- Narod SA. Genetics of breast and ovarian cancer. Br Med Bull 1994; 50: 656-76.
- Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995; 72: 805-12.
- Steel CM. Cancer of the breast and female reproductive tract. In: Rimoin DL, Connor JM, Peyritz RE, eds. Emery and Rimoin's Principles and Practice of Medical Genetics, 3rd edn. New York: Churchill Livingstone, 1996; 1501-23.
- Birch JM. Familial cancer syndromes and clusters. Br Med Bull 1994; 50: 624-39.
- Nelen MR, Padberg GW, Peeters EAJ, et al. Localisation of the gene for Cowden disease to chromosome 10q22-23. Nature Genet 1996; 13: 114-6.
- Bishop DT, Hopper J. AT-tributable risks? Nature Genet 1997; 15: 226.
- Friend SH, Breast cancer susceptibility testing: realities in the post-genomic era. Nature Genet 1996; 13: 16-7.
- Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi jewish breast cancer families. Nature Med 1996; 2: 1179-83.
- Campbell H, Mackay J, Porteous M. The future of breast and ovarian cancer genetics clinics. BMJ 1995; 311: 1584-5.
- Beatson GT. On the treatment of inoperable cases of cancer of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; ii: 104-7.
- Jensen EV, De Sombre ER, Mechanism of action of female sex hormones. A Rev Biochem 1972; 41: 203-30.
- Going JJ, Anderson TJ, Battersby S, McIntyre C. Proliferative and secretory activity in the human breast during natural and artificial menstrual cycles. Am J Pathol 1988; 130: 193-204.
- Langdon SP, Simpson BJB, Bartlett JMS, Miller WR. Hormonal, growth factor and cytokine control of ovarian cancer. In: Langdon SP, Miller WR, Berchuck A, eds. Biology of Female Cancers. Boca Raton: CRC Press, 1997; 115-31.
- Herbst AL. Adenocarcinoma of the vagina: association of maternal stilboestrol therapy with tumour appearance in young women. N Engl J Med 1971; 284: 878-83.
- McPherson K, Doll H. Oestrogens and breast cancer: exogenous hormones. Br Med Bull 1990; 47: 484-92.
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.
- Romieu I, Willett WC, Colditz GA, et al. A prospective study of oral contraceptive use and the risk of breast cancer in women. J Natl. Cancer Inst. 1989; 81: 1313-21.
- Greenberg ER, Barnes AB, Resseguie L, et al. Breast cancer in mothers given diethylstilbestrol in pregnancy. N Engl J Med 1984; 311: 1393-7.
- Colditz GA, Rozner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 1996; 88: 365-71.
- Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among young women. J Nat] Cancer Inst 1995; 87: 827-35.
- Bergkvist L, Adami H-O, Persson I, et al. The risk of breast cancer after estrogen and estrogenprogestin replacement. N Engl J Med 1989; 321: 293-7.
- Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67-72.
- Colditz GA, Stampfer MJ, Willett WC, et al. Type of postmenopausal hormone use risk of breast cancer: 12 year follow-up from the nurses health study. Cancer Causes Control 1992; 3: 433-9.
- Jacobs HS, Loeffler FE. Postmenopausal hormone replacement therapy. BMJ 1992; 305: 1403-8.
- McPherson K. Breast cancer and hormonal supplements in postmenopausal women. BMJ 1995; 311: 699-70.
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-59.
- La Croix AZ, Burke W. Breast cancer and hormone replacement therapy. Lancet 1997; 350: 1042-3.
- Vessey M, Metcalfe A, Wells C, et at. Ovarian neoplasms, functional ovarian cysts and oral contraceptives. BMJ 1987; 294: 1518-20.
- Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Lancet 1988; ii: 1331-5.
- Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of 3 European case control studys of epithelial ovarian cancer: III oral contraceptive use. Int J Cancer 1991; 49: 61-5.
- The Cancer and Steroid Hormone study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987; 316: 650-5.
- Mant JWF, Vessey MP. Mortality trends in ovarian cancer. In: Lawson FG, Neijt JP, Swenerton KD, eds. Epithelial Cancer of the Ovary. London: BMJ Publications, 1995; 1-12.
- Black RJ, Sharp L, Kendrick SW. Trends in cancer survival in Scotland 1968-1990. Information and Statistics Division, Common Services Agency, The National Health Service in Scotland, Edinburgh, 1993.
- Harris JR, Lippman ME, Veronesi U, et al. Breast cancer. N Engl J Med 192; 327: 319-28.
- Coleman MP, Esteve J, Damiecki P, et al. Trends in cancer incidence and mortality. Lyon, France: [ARC Publications, 1993, no. 121.
- Eeles R. Testing for the breast cancer predisposition gene BRCA1: documenting the outcome in gene carriers is essential. BMJ 1996; 313: 572-3.
- Mackay J, Crosbie AEC, Steel CM, et al. Clinical and ethical dilemmas in familial ovarian cancer. In: Sharp F, Blackett T, Leake R, Berek J, eds. Ovarian Cancer. London: Chapman & Hall, 1996; 81-9.
- Calman KC. Cancer: science and society and the communication of risk. BMJ 1996; 313: 799-802.
- Law J. Risk and benefit associated with radiation dose in breast. screening programmes. Br J Radiol 1995; 68: 870-6.
- Mettler FA, Upton AC, Kelsey CA, et al. Benefit versus risks from mammography: a critical reassessment. Cancer 1996; 77: 903-9.
- Curtis RE, Boice JD, Shriver DA, et al. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996; 88: 832-4.
Journal of Nutritional & Environmental Medicine
Volume 8, 1998 - Issue 2